The immune checkpoint-mediated drug development has aroused great attention in different clinical settings. To meet the challenging requirements, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide a series of cell-based binding assays to test the binding and interaction of immune checkpoints. Till now, we have accomplished many projects for identifying the efficacy and safety of immune checkpoints.
Immune checkpoints are a group of regulators that play a pivotal role in regulating immune responses. In general, maintaining immune homeostasis is a key part of disease treatments. The balance of these immune checkpoints, such as PD-1, PD-L1, CD27, CD80, BTLA, LAG-3, CD40, LIGHT, CTLA-4, and NKG2A, has become research hotspots in preventing inflammatory tissue damage and disease progression.
To date, a wide variety of immune checkpoints and their pathways have been considered as targets for cancer immunotherapy due to their promising role in regulating T cell responses, chronic infections, as well as tumor-associated antigens. Drugs or inhibitors blocking these pathways have been approved and broadly used in treating many malignancies and have shown durable anti-tumor immunity in both preclinical and clinical trials.
In the past few years, pilot studies have demonstrated that blocking the interaction or binding between immune checkpoint proteins and their ligands can restore the functions of immune cells and enhance tumor elimination. Consequently, Creative Biolabs has developed a comprehensive battery of cell-based binding assays to evaluate the blocking ability of drug candidates and detect the specificity of the immune checkpoint proteins or their ligands.
Besides, we have also developed a panel of novel cell-based assays for drug screening, potency evaluation, and stability assessment. The data has indicated that our assays overcome the limitations of primary cell-based assays, which are available in "easy-to-use" format and have shown high specificity, sensitivity, and reproducibility.
Creative Biolabs is a leader in drug discovery targeting immune checkpoints and has focused on providing cell-based binding services for years. We have experienced experts and advanced platforms that can provide excellent services.
Creative Biolabs provides a global service chain for worldwide customers in the field of immune checkpoint research. We guarantee the most satisfactory results for our customers all over the world. If you are interested in our services, please feel free to contact us. Separate services or integrated end-to-end solutions are all welcomed.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.
Our customer service representatives are available 24 hours a day, 7 days a week.
USA
Tel:
Fax:
Email:
Copyright © 2024 Creative Biolabs. All Rights Reserved.
